Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Susan Short : one of the co-signees of the JAMA “Comment”. Comment November 30, 2022 The need to report as-planned analyses and the weakness of historical controls Dr. Matt Williams, London Dr. Paul Sanghera, Birmingham Prof. Susan Short, Leeds Dr. Anup Vinayan, London Dr. Juliet Brock, Oxford Dr. Chris Herbert, Bristol Dr. Joanne Lewis, Newcastle Dr. Shaveta Mehta, Liverpool https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
Not much, IMO There are 81 events (placebo group n=99) https://investorshub.advfn.com/uimage/uploads/2022/5/11/jjgyh5-10-22-Slide-11.png I count 33 events beyond 7.6 months from randomization. IMO, there are 48 events between 0 and 7.6 months from randomization. (33 + 48 = 81 events) In the optimal scenario 33 placebo patients (with recurrence beyond 7.6 months) could cross over, IMO. NOTE: PFS event = an event being either disease progression or death. That's why i believe that mPFS of the 64 crossovers is also around 7.6 months from randomization. You say:
flipper44, EANO ANNUAL REPORT 2021 Professor Susan Short, a Professor of neuro-oncology at Leeds University, has been elected by the Executive EANO Board to become the next EANO President (2022-2024)
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma A Phase 3 Prospective Externally Controlled Cohort Trial
Comment November 30, 2022 The need to report as-planned analyses and the weakness of historical controls Dr. Matt Williams, London Dr. Paul Sanghera, Birmingham Prof. Susan Short, Leeds Dr. Anup Vinayan, London Dr. Juliet Brock, Oxford Dr. Chris Herbert, Bristol Dr. Joanne Lewis, Newcastle Dr. Shaveta Mehta, Liverpool https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
The Fourth Biennial World Summit of Brain Tumour Patient Advocates at the National Institutes of Health (NIH) in Bethesda, Maryland, October 9 to 12, 2019. Plenary session 10 at the IBTA World Summit Access to Therapies (compassionate use, off-label use, regulatory approval and HTA) Panellists: Dr. Mark Gilbert, Linda Powers, Irina Odnoletkova, Suzanne Demko (FDA), David Jenkinsson.
Critical review of the report on the DCvax-L trial: the trial did not meet its prospectively defined endpoint and post-hoc analyses with poorly selected external controls do not replace a proper prospective trial https://t.co/3kJnHYW4P6
Critical review of the report on the DCvax-L trial: the trial did not meet its prospectively defined endpoint and post-hoc analyses with poorly selected external controls do not replace a proper prospective trial https://t.co/3kJnHYW4P6
Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma: What happened to the evidence? T. Olivier (a-b) , D. Migliorini (a-b) a Department of Oncology, Geneva University Hospital, 4, Gabrielle-Perret-Gentil Street, 1205 Geneva, Switzerland b Translational Research Center in Oncohaematology, University of Geneva, Geneva, Switzerland
Asgeir Jakola - Neurosurgeon/Professor March 31, 2023
Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma. A Randomized Clinical Trial Published: March 31, 2023. doi:10.1001/jamanetworkopen.2023.4149 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2802966 Patients were recruited at 7 study sites in Sweden and 2 sites in Norway from January 16, 2017, until November 15, 2020.
Landmark survival rate(%) in rGBM -DCVax-L trial. For 64 patients with rGBM receiving DCVax-L survival at 6, 12, 24, and 36 months, the proportions alive are 90.6% (vs 62% SOC group in the Disulfiram Study), 54.1% (vs 27% SOC group in the Disulfiram Study), 20.7% (vs 5% SOC group in the Disulfiram Study), and 11.1% respectively, which is really very, very impressive.
The Windsor Framework contains some good news for patients in Northern Ireland and the UK pharmaceutical industry more generally.
So, if an ATMP has been licensed by the MHRA, which includes for Northern Ireland, then the question is: how can it be different in the rest of EU from Northern Ireland? Will this led to the approach where if an ATMP has been licensed by the MHRA, the European Medicines Agency (EMA) will do a light-touch review, and only raise objections if there is a serious public health concern recognized?
Happy 70th Birthday Dad! This girl knows she won the Dad lottery! Thank you for always supporting my dreams and teaching me to believe that with hard work and focus, everything is possible. Lots of love, your little girl ❤️ pic.twitter.com/VxBgGyBOxc
On March 1, one position left at AdventBio- "Cleanroom Technician". This morning (UK time) "the Patient Coordinator and Liaison Officer" was one of the 4 vacancies. It was removed from current positions available this afternoon.
On October 9, 2012, one of those 10-year-old survivors was diagnosed with GBM in the motor-sensory cortex of his brain. Like that, the flying career he started as a teenage kid vanished. On October 9, 2019, he celebrated 7 years of survival while sitting in a cockpit again and flying to Hawaii. He is still doing fine.
One of the patients in this combo trial had her surgery on June 7, 2021. She's still alive. She is one of 4 censors between 410 and 490 days after surgery on the OS curve, IMO She was first diagnosed with GBM on May 24, 2019 https://twitter.com/ATLnsider/status/1600002351191859200/photo/2
Aug 26, 2019 Cognate BioServices Secures Growth Capital Investment from EW Healthcare to Continue to Expand Commercial Manufacturing Capacity and Services for the Cellular Therapies Industry
Dr. Kathryn Nevel talks with Dr. Linda Liau about the use of autologous tumor lysate-loaded dendritic cell vaccination for the treatment of newly diagnosed and recurrent glioblastoma.